Adverse Effect Management for CAR T-Cell Therapy and Bispecifics in R/R MM

Opinion
Video

In a discussion with the Oncology Brothers on the treatment of patients with relapsed/refractory multiple myeloma, Samer Al'Hadidi, MD, discusses adverse effects associated with CAR T-cell therapy and bispecific antibodies.

Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Related Content
Data from DREAMM-7 and DREAMM-8 support the marketing authorization application for the belantamab mafodotin combinations in multiple myeloma.

EMA Accepts Application for Belantamab Mafodotin in R/R Multiple Myeloma

Russ Conroy
July 19th 2024
Article

Data from DREAMM-7 and DREAMM-8 support the marketing authorization application for the belantamab mafodotin combinations in multiple myeloma.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Leveraging CAR T-Cell Therapy Advancements in R/R Multiple Myeloma

Leveraging CAR T-Cell Therapy Advancements in R/R Multiple Myeloma

ONCOLOGY Staff
July 13th 2024
Article

Experts in multiple myeloma discussed the evolving role of CAR T-cell therapy for patients with relapsed/refractory disease.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD;Luciano Costa, MD, PhD;Timothy Schmidt, MD
August 14th 2023
Podcast

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

Zachary M. Avigan, MD;Joshua Richter, MD
June 14th 2024
Article

The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.

Prophylactic Tocilizumab Combo Reduces CRS in Relapsed/Refractory Myeloma

Prophylactic Tocilizumab Combo Reduces CRS in Relapsed/Refractory Myeloma

Russ Conroy
June 5th 2024
Article

Data support prophylactic treatment with tocilizumab as an option to mitigate the risk of CRS for outpatient dosing of teclistamab.